Central Nervous System Immune Reconstitution Inflammatory Syndrome
- 31 October 2013
- journal article
- research article
- Published by Springer Nature in Current Infectious Disease Reports
- Vol. 15 (6) , 583-593
Abstract
Central nervous system immune reconstitution inflammatory syndrome (CNS-IRIS) develops in 9 %–47 % of persons with HIV infection and a CNS opportunistic infection who start antiretroviral therapy and is associated with a mortality rate of 13 %–75 %. These rates vary according to the causative pathogen. Common CNS-IRIS events occur in relation to Cryptococcus, tuberculosis (TB), and JC virus, but several other mycobacteria, fungi, and viruses have been associated with IRIS. IRIS symptoms often mimic the original infection, and diagnosis necessitates consideration of treatment failure, microbial resistance, and an additional neurological infection. These diagnostic challenges often delay IRIS diagnosis and treatment. Corticosteroids have been used to treat CNS-IRIS, with variable responses; the best supportive evidence exists for the treatment of TB-IRIS. Pathogenic mechanisms vary: Cryptococcal IRIS is characterized by a paucity of cerebrospinal inflammation prior to antiretroviral therapy, whereas higher levels of inflammatory markers at baseline predispose to TB meningitis IRIS. This review focuses on advances in the understanding of CNS-IRIS over the past 2 years.Keywords
This publication has 88 references indexed in Scilit:
- Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) in HIV Patients with Culture Confirmed Pulmonary Tuberculosis in India and the Potential Role of IL-6 in PredictionPLOS ONE, 2013
- Frequency, Severity, and Prediction of Tuberculous Meningitis Immune Reconstitution Inflammatory SyndromeClinical Infectious Diseases, 2012
- Immune reconstitution inflammatory syndrome: the trouble with immunity when you had noneNature Reviews Microbiology, 2012
- Integration of Antiretroviral Therapy with Tuberculosis TreatmentNew England Journal of Medicine, 2011
- Timing of Antiretroviral Therapy for HIV-1 Infection and TuberculosisNew England Journal of Medicine, 2011
- Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitionsThe Lancet Infectious Diseases, 2010
- Paucity of Initial Cerebrospinal Fluid Inflammation in Cryptococcal Meningitis Is Associated with Subsequent Immune Reconstitution Inflammatory SyndromeThe Journal of Infectious Diseases, 2010
- Cost‐Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV‐Infected Persons with a CD4+Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource‐Limited SettingsClinical Infectious Diseases, 2010
- Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South AfricaClinical Infectious Diseases, 2009
- Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsThe Lancet Infectious Diseases, 2008